Assessing the Global Burden of IgA Nephropathy (IgAN) in Patients Receiving Hemodialysis: A Real-World Study Using DOPPS Data

Assessing the Global Burden of IgA Nephropathy (IgAN) in Patients Receiving Hemodialysis: A Real-World Study Using DOPPS Data

This study leverages the global Dialysis Outcomes and Practice Patterns Study (DOPPS) database to generate real-world evidence on the burden of IgAN in patients who progress to kidney failure and require maintenance hemodialysis (HD). We will first aim to understand prevalence of IgAN in a global cohort of in-center HD patients. The second and third objectives aim to quantify the patient burden of IgAN using a two-step approach: first, a detailed single-arm evaluation of outcomes within the IgAN population; second, a matched comparison to the broader HD population.

Inclusion Criteria:

• Age ≥ 18 years at the time of enrollment
• Receiving in-center HD treatment at a participating dialysis facility
• Able to provide informed consent, if required by local regulations or ethics boards

Exclusion Criteria:

-